PFE · Earnings call · 2026Q3T · Full report

New Product Market Growth

PFIZER INC · 2026-11-03 · Importance 26 · Surprise 24

Management attributed its growth trajectory in part to continued growth of new and acquired products, citing expanding markets, increasing penetration and opportunities to add indications and reach more patients. It identified obesity and oncology products as areas where management sees differences from external expectations, while emphasizing that its trajectory is not dependent on one product or therapeutic area. CEO Albert Bourla said Nurtec was nearing a $2 billion annualized level, while citing a Street estimate of almost $2.5 billion by 2030. He also contrasted a $5 billion Street forecast for a competing product with a $600 million estimate for Pfizer’s Elrexfio, while noting that its comparative efficacy and tolerability profile remains to be proven.

Key facts

• Pfizer CEO said Nurtec was close to $2 billion on an annualized basis, while the Street forecast Pfizer's Nurtec sales at almost $2.5 billion by 2030.